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Abstract: Medicated foams and film forming systems are dosage forms formulated to undergo to a controlled 
metamorphosis when applied on the skin. Indeed, due to the presence of propellant or a particular air-spray 
foam pump, a liquid can generate a foam when applied on the stratum corneum, or a liquid or conventional 
dosage form can form on the skin a continuous film as a consequence of the solvent evaporation. Thanks to 
these controlled modifications, the drug thermodynamic activity increases favoring the skin penetration and, 
therefore, the bioavailability with respect to conventional semi-solid and liquid dosage forms. Furthermore, the available 
clinical data also evidence that these dosage forms improve the patient’s compliance. The main formulative aspects of 
medicated foams and film forming systems are reviewed with the aim to underline the possible advantages in terms of 
biopharmaceutical performances and patient’s adherence.  
Keywords: cutaneous administration, dosage forms, film forming system, medicated foam, skin permeation, substantivity, 
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1. INTRODUCTION 
 The most common dosage forms intended to be applied 
on the skin are solutions, suspensions, creams, gels, 
ointments, and lotions. They are usually perceived as safe 
with minimal risk of systemic exposure and associated side 
effects. However, to design an effective topical drug delivery 
could be challenging since the penetration is limited by the 
peculiar barrier properties of the stratum corneum. Indeed, 
being regulated by the Fick's law, the penetration is 
proportional to the drug thermodynamic activity that 
provides the driving force for the passive diffusion process 
[1]. Therefore, the simplest strategy to improve the drug 
permeation through the skin is to increase the permeant 
concentration in the dosage form until saturation. Obviously, 
the development of a supersaturated system, having a 
chemical potential greater than that of the corresponding 
saturated systems, can furtherly enhance the permeation 
through the stratum corneum [2]. The efficacy of such 
approach was widely studied using solutions [3] or applied 
to develop patches [4], but supersaturation also 
spontaneously occurs in semisolid preparations containing 
water, e.g. creams and gels, in which the loss of water, due 
to the skin penetration or evaporation, can increase the drug 
concentration into the pharmaceutical form. However, the 
drug chemical potential in these formulations is not the only 
factor influencing the permeation process, but also the 
“water activity” (i.e. the thermodynamic energy status 
represented as the ratio of partial vapour pressure of water in 
the formulation and vapour pressure of pure water) has to be 
considered. The greater the value, the higher the flux of the 
permeant [5]. In other words, the drug release from topical 
formulations is influenced not only by the formulation 
viscosity and the drug thermodynamic activity, but also by 
the physico-chemical characteristics of the excipients which 
influence the water activity. As an example, the inclusion of 
small molecule humectants, e.g. propylene glycol, dropdown 
the water activity and, therefore, significantly affects the 
drug permeation [5]. In the case of semisolid preparations, 
the skin permeation is furtherly complicated by their 
continuous metamorphosis. Indeed, the components of the 
pharmaceutical dosage form can penetrate the stratum 
corneum, evaporate or mix with the lipids of skin surface. 
These unpredictable modifications of the vehicle 
composition lead to changes of drug solubility and, 
therefore, drug thermodynamic activity as well as water 
activity [3, 6]. In this framework, film forming dosage forms 
and medicated foams, being appositely designed to have a 
controlled metamorphosis when applied on the skin, can 
permit a reproducible drug absorption since both the 
variations in water activity and the permeant thermodynamic 
activity are less relevant with respect to other liquid and 
semisolid dosage forms [5]. These systems enable to 
generate an (albeit transient) supersaturated system on the 
skin surface and/or in the upper stratum corneum since, the 
drug concentration in the vehicle increases due to the 
propellant loss or solvent evaporation upon application and 
spreading on the skin.  
In this review, we describe the main features of medicated 
foams and film forming systems, as well as their main 
permeation mechanisms. Furthermore, the published 
available data on the potentialities to improve the patient’s 
adherence and/or compliance are discussed. Reviewed 
articles were obtained from the PubMed, SciFinder and 
Scopus online databases. 
MEDICATED FOAMS 
Medicated foams (MF) are exploited to administrate several 
active ingredients and drug loaded lipid nanoparticles, even 
if most of the commercial foams deliver corticosteroids or 
NSAIDS (Table 1). 
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Table 1 – Literature data on medicated foams vs. other cutaneous pharmaceutical forms.
Drug Set-up Main findings year ref 
In vitro 
Clindamycin Human skin; flow through diffusion 
cells vs gel 
Greater accumulation after 24 h and earlier onset 
than clindamycin gel 
2005 7 
Clobetasol 
propionate 
Human skin; flow-through diffusion 
cells vs cream, emollient cream, lotion, 
and solution 
A faster initial permeation of clobetasol compared 
with the other vehicles. In the first 14 h, foam 
delivered a similar amount of drug (J and AUC) 
compared with the emollient cream and a greater 
amount of drug compared with the solution, 
cream, and lotion. The foam vehicle delivered 
more clobetasol than the other formulations 
2005 7 
Clobetasol 
propionate 
Different anatomic region of human 
skin vs foam, cream, and emollient 
cream 
Foam needs the least time to overcome anatomic 
region variations (= thickness), whereas cream 
and ointment take a longer time for the onset of 
delivery 
2005 7 
Ketoconazole Silastic membranes; static Franz cells Penetration 11-fold higher vs cream 2005 7 
Metronidazole In vitro skin penetration study; excised 
human skin; a flow-through diffusion 
cell 
The total cutaneous penetration of metronidazole 
was two- to three-fold higher than the reference 
cream 
2006 8 
Vitamin E 
acetate  
In vitro silicone membrane penetration 
study; in vitro skin tape stripping 
The increase in Pluronic surfactant concentration 
after application modified the lipid nanoparticles 
to enable drug release and penetration into skin 
2009 9 
Benzoyl 
peroxide  
In vitro silicone membrane penetration 
study 
Benzoyl peroxide loaded in nanoparticles was 
chemically stable over a 7 d period. Foams 
allowed to obtain a comparable flux to 
commercial gels and creams, but at much lower 
concentration 
2010 10 
Minoxidil  In vitro silicone membrane penetration 
study 
Foam delivered significantly more drugs across 
the membrane than the saturated aqueous 
solution. The cumulative permeant amount of 
drug depends on the surfactant concentration in 
the foam 
2010 11 
Calcipotriene + 
betamethasone 
Raman imaging After propellant evaporation, a supersaturated 
environment was created, where drug crystals 
were absent for at least 26 h. 
2016 12 
Thiocolchicoside Skin; Saarbruecken penetration model-
based cells 
At each incubation time, significant higher 
amounts of drug were detected for the foam 
formulation 
2008 13 
Cholecalciferol 
+ salicylic acid 
Pig-ear test for irritancy potential 
evaluation 
Incorporation of two incompatible drugs 2017 14 
 In vivo 
Minoxidil Caucasian male volunteers aged 
between 22 and 29 years. Every 10 d, 
0.007±0.002 g foam was applied to the 
chest and the occipital region of the 
scalp 
Hair follicles contribute to the penetration of 
minoxidil into the blood circulation since faster 
absorption of minoxidil was detected when the 
hair follicle orifices were open. 
2010 15 
Betamethasone 
valerate 
A Phase II, randomised, single-centre, 
blinded, right-left comparison within 30 
patients with mild-to-moderate psoriasis 
After 3 wk, statistical significant improvement 
from baseline in thickness, redness, scaling, itch 
and global score 
2006 8 
Tarazotene  Phase I study Reduced systemic levels of tazarotenic acid in 
comparison to the marketed gel 
2013 16 
Azelaic acid A Phase 3 randomized, double-blind, Azelaic acid foam at 15% resulted efficient and 2015 17 
Tabella formattata
Formattato: Colore carattere: Rosso
Tabella formattata
Formattato: Colore carattere: Rosso
4    Journal Name, 2018, Vol. 0, No. 0 Principal Author Last Name  et al. 
vehicle controlled, parallel-group, 
multicenter study with participants with 
moderate to severe papulopustular 
rosacea 
safe in patients with papulopustular rosacea 
Azelaic acid Eight dogs with nonseasonal 
mild/moderate canine atopic dermatitis 
were treated twice weekly with either a 
commercial foam or a foam/mousse 
containing components from plant 
extracts, for 14 d. After a wash-out 
period of 14 d received the other foam 
in a randomized blinded study 
A significant improvement in both skin lesions 
and pruritus was noted for both treatment groups. 
This method of product delivery is easy to use for 
owners, improving compliance in practice 
2018 18 
Econazole 
nitrate 
Two randomized, double-blind, 
parallel-group, vehicle-controlled, 
multicenter studies enrolled males and 
females ≥12 y old with a clinical 
diagnosis of interdigital tinea pedis and 
baseline fungal culture positive for a 
dermatophyte. Subjects applied 1% 
econazole nitrate foam (n=246) or foam 
vehicle (n=249) once daily for 4 wk 
The drug loaded foam exhibited superiority over 
foam vehicle with a high mycologic cure rate for 
all pathogens evaluated. Econazole nitrate foam 
1% was safe and well tolerated with a safety 
profile comparable with the foam vehicle 
2014 19 
Tazarotene Two randomized, double-blind, vehicle-
controlled, parallel-group studies were 
randomly treated with either0.1% 
tazarotene foam or vehicle foam once 
daily for 12 wk 
Tazarotene foam significantly reduced the 
number and severity of acne lesions after 12 wk 
and had a safe and acceptable tolerability profile 
2013 20 
 
MEDICATED FOAMS 
Medicated foams (MF) are exploited to administrate several 
active ingredients and drug loaded lipid nanoparticles, even 
if most of the commercial foams deliver corticosteroids or 
NSAIDS to treat psoriasis and muscle-skeletal disorders, 
respectively (Table 1). Generally speaking, foams can be 
produced by (i) mechanical agitation of a liquid or a solution 
(“whipping”); (ii) injecting a stream of gas or liquid or the 
mixture into a liquid (“bubbling”) and (iii) sudden pressure 
reduction [21]. The latter is typical of MF intended to 
cutaneous application, which are generally prepared by 
adding to a canister the formulation consisting in a solution, 
O/W emulsion, or suspension, containing the active 
ingredient(s). Then, the propellant is forced, under pressure 
and/or at low temperature, into the container, which is sailed 
to make the final MF products.  
After actuation, the propellant evaporates producing a liquid 
or semi-solid foam product that is expanded with air. As 
propellant(s) can also act as solvents, once applied on the 
skin, the concentration of the drug in the vehicle increases, 
thus enhancing the absorption of the active ingredient 
through the skin [22]. The “bubbling” approach has the 
advantage to avoid the environmental issues related to the 
use of propellants, even if the increase of drug concentration 
is lost. In this case, the pressure required to generate the 
foam is provided by an “air-spray foam pump” and 
surfactants are the most relevant components of the 
formulation [14]. Another propellant-free approach is based 
on the formulation of a semi-solid gel (“Bag-in-can” 
system), which produces a foam when it is rubbed on the 
body. These products usually contain a low boiling 
hydrocarbon, such as isopentane (boiling point 28 °C) 
which evaporates after application at body temperature, 
forming a foam. Because of the low boiling point of 
isopentane, these formulations are packed in pressurized 
containers [23], but a barrier system separates the product 
with solubilized isopentane from the pressurizing gas. The 
external pressure is needed to dispense the product and to 
keep isopentane in the product. Even if a high pressure is 
necessary to deliver the product, it does not influence on the 
quality of the medicated foam after actuation.  
 
2.1 Formulation Aspects 
To design a MF, propellants play a key role since they 
evaporate at atmospheric pressure, generating the foam, and 
the velocity of this process is dependent on the rate of 
propellant evaporation. Hydrocarbons (e.g. n-butane, 
isobutane, n-propane or mixtures thereof) at the 
concentration of 3-12% [23] can produce a foam of adequate 
quality, despite the potential safety hazard due to the high 
flammability and explosivity. These propellants are liquefied 
under pressure and their blends have a wide interval of 
boiling points up to -42 °C, without the metering problem of 
compressed gases. There are also systems containing 
immediately evaporating propellants, and propellants which 
evaporate with a delay (e.g. n-pentane, isopentane, 
isobutane), causing a cooling effect on the skin surface. 
Hydrofluroalkanes (HFAs) have been gaining more attention 
for pharmaceutical application since they present a high 
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vapor pressure without safety and environmental concerns 
[24, 25]. 
Essential components to generate and stabilize a foam are 
also foaming agents, namely surface-active agents (e.g. 
surfactants or certain polymers of different nature including 
proteins [26]) which orient themselves at the air-water 
interface forming micelle on valve actuation. When they are 
adsorbed to this interface, the surface tension decreases, and 
the surface pressure increases, leading to the foam formation. 
Higher values for surface pressure and lower values for 
surface tension do not always lead to an increase of foam 
stability, for which the concentration of foaming agent in the 
adsorbed layer is one of the most important factors. During 
foam formation, a rapid adsorption of the foaming agent is 
desirable. However, in this phase, the concentration of 
foaming agents in the bulk phase decreases with the increase 
of the surface area, leading to the decrease of the 
concentration gradient and, therefore, of the diffusion rate. 
Therefore, to ensure a rapid diffusion of a foaming agent to 
the surface, high concentrations of foaming agents and a low 
viscosity of the liquid phase are necessary. For some 
foaming agents, the maximum capacity of foam formation is 
obtained at a concentration equal or close to the critical 
micelle concentration [27] or when they are used in 
combination [28].  
A viscosity-modifying agent in the concentration range of ∼ 
0.05 – 2.0% is required to facilitate the creation of a foam 
with desirable texture and optimum spreading properties [8]. 
These excipients are often selected among natural (e.g. 
xanthan gum), semi-synthetic (e.g. cellulose ethers) and 
synthetic (e.g. poly(vinyl pyrrolidone)) polymers.  
Besides these components, other excipients can also be 
incorporated, depending on the active agent and the required 
foam characteristics. For example, to formulate ionizable 
drugs (e.g. minoxidil) an acid can be employed to maintain 
the pH in the most favorable range [11]. 
Beside the approach to obtain the foam, an assessment of the 
general appearance as well as the stability are important 
factors for cosmetic acceptability of foams. 
There are two fundamental parameters determining the 
structure and behavior of the foams: the gas volume fraction 
and the bubble diameter. Generally, the fraction of gas 
volume in the foam is between 0.5 and 0.9, while the bubble 
size is between 0.1 and 3 mm depending on how the foam is 
generated and the excipients used [23].  
The stability of product and foam should be evaluated prior 
to dose application (i.e. inside the canister) and post-dose 
application, respectively. However, the former is often 
neglected due to practical problems related to the 
explosiveness and flammability of certain propellants. The 
latter is related to three main factors, which can occur 
concurrently: Ostwald ripening (disproportionation), 
drainage and film rupture. Ostwald ripening involves the 
transport of gas from small to large bubbles, so that the 
smaller air bubbles dissolve, while the larger bubbles 
increase in size. The liquid drainage is the flow of liquid 
through channels between the bubbles, which is usually 
driven by capillary (surface tension) forces and is resisted by 
viscous forces. It depends on the individual channels and on 
the type of surfactant used to create the foam. The 
consequent thinning of the channels that separate the foam 
bubbles, and the elasticity of the lamellae (i.e. the thin layer 
of the continuous liquid film separating the faces of two 
adjacent polyhedral bubbles), increases the occurrence of 
Ostwald ripening and film rupture. The rupture of the liquid 
film separating the bubbles leads to their coalescence and 
complete collapse of the foam structure. Generally, foams 
with a higher fraction of gas volume are more stable because 
liquid drainage is delayed. However, it is difficult to develop 
a general theory concerning the stability of foams, since 
many dynamic and static factors are involved [23]. 
Instability can be also increased by some excipients added to 
improve the drug solubility or to obtain a peculiar 
formulation. As an example, oils, alcohols or organic 
solvents, which are normally not very soluble in water, 
diffuse at the level of the lamellae, increase the drainage of 
the liquid and consequently make them thin, increasing the 
fragility of the foam [29]. Moreover, the failure of the 
structure for hydroethanolic foams, when a critical 
temperature is attained, is rapid and occurs at lower 
temperatures compared with emulsion foams. Aqueous 
foams showed higher temperature stability than 
hydroethanolic or emulsion emulsion-based foams [30]. 
There are several excipients that can be added to improve the 
foam stability: surfactants at the interfaces can form a strong 
and elastic interfacial film around the foam bubbles and thus 
retard coalescence; hydrophilic polymers with high 
molecular weight can increase the viscosity reducing the 
drainage; electrolytes can cause the electrostatic stabilization 
of the bubbles. Moreover, both temperature and pressure 
influence the drainage speed by altering the liquid bulk 
viscosity [23].  
Despite stability is an important factor for the cosmetic 
acceptability of foams, the main pharmacopoeias do not 
report any information on these aspects. For example, the 
European Pharmacopoeia 9th Edition suggests two 
characterization methods in the monograph “Medicated 
Foams” (Musci medicati). The former is based on the 
estimation of the relative foam density as an indication of the 
foam firmness; the latter is related to the foam expansion 
time as a parameter for the foamability of the formulation. 
Density of the produced foam is determined by weighing a 
predefined volume of foam compared to the weight of the 
same volume of water. For determination of foam expansion 
time, a foam volume is fed in a burette and foam expansion 
is followed within a defined time.  
The problems of measuring the foam stability depend mainly 
on the insufficient characterization of the microscopic 
processes involved, essentially the collapse of the foam 
through the loss of solvent. In this view, the General 
Chapters Dosage Forms Expert Committee [31] is 
investigating the inclusion in the USP of a general chapter on 
pharmaceutical foams providing guidance on important 
quality and performance attributes of this dosage form. Rate 
of foam liquid drainage, and collapse can be observed by 
dispensing a foam into a graduated cylinder. Observations 
are made of the volume occupied by the freshly dispensed 
foam and after a defined period, e.g., 30 min, of the aged 
foam and the drained liquid. 
3. FILM FORMING SYSTEMS 
 A film-forming system (FFS) is defined as a liquid or 
semi-solid dosage form which produces a polymeric film 
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after application on the skin due to the rapid evaporation of 
the solvent [32]. Upon evaporation the polymer chains 
interpenetrate to form a continuous film. This event occurs at 
a well-defined polymer concentration [33-36], which is 
dependent on the molecular volume of the macromolecules 
in the solvent, usually expressed as intrinsic viscosity [37]. 
In the case of polymeric latex, the solvent evaporation causes 
coalescence of the polymer particles and, therefore, the 
interpenetration of the polymer chains.  
This process is strongly linked to the dimensions of the 
polymeric particles involved, but perhaps the most critical 
point is the temperature. In fact, the nature of this process 
provides that there is a minimum film-forming temperature 
(MFFT), below which the dispersion, once in contact with 
the skin, forms an opaque and slightly homogeneous film. It 
is therefore necessary that the solvent evaporation occurs at a 
temperature higher than that of the MFFT, to guarantee the 
coalescence of the particles. The value of MFFT depends 
strictly on the polymer type and particle size.  
Because of the metamorphosis of such dosage forms, there is 
a considerable increase in the concentration of the drug in 
the residual film left on the skin surface, leading to the 
possible drug supersaturation on the skin or in the stratum 
corneum [38]. Therefore, the drug permeation profile usually 
comprises a rapid uptake of drug when solvent(s) 
evaporate(s) or penetrate the skin, followed by a slower 
profile governed by release from the residual film. In 
addition, some of these formulations can also determine the 
formation of a drug "reservoir" in the stratum corneum [39] 
allowing to obtain a greater and more prolonged absorption 
with only one application per day [40, 41]. Efforts carried 
out to design FFS the transdermal administration of different 
classes of drugs (e.g. steroid hormones, local anesthetics, 
NSAID, analgesics and antiemetic agents Table 2), 
evidenced that the optimal formulation should quickly dry on 
the skin; the formed film should not adhere to the patient's 
clothes, and its mechanical properties should overcome the 
tangential stress due to the body movements. 
3.2 Formulation aspects 
Independently of the formulations to be applied on the skin, 
namely solutions, sprays, gels and emulsions, a broad range 
of film-forming materials, both of synthetic and natural 
origin has been tested to design FFS (Table 2). Among those 
of synthetic origin, there are cellulose derivatives, polymers 
or copolymers of acrylic acid, polymers or copolymers of 
methacrylic acid, vinyl polymers and silicones [42]. Instead, 
those of natural origin are less used, even though recently the 
research was focused to the exploitation of biodegradable 
natural polymers [43], e.g. regenerated silk fibroin [44] and 
chitosan [45]. Besides polymers, two other main components 
have to be considered and balanced to design an efficacious 
and safe FFS: solvent(s) and plasticizer(s). Indeed, the 
dosage form should quickly dry on the skin and the MFFT 
should be below the skin surface temperature (32 °C). After 
formation, the formed film, consisting of a thin layer of 
polymer perfectly transparent, should adhere to the skin, but 
not stick to clothes [46]. 
The mechanical properties of the formed film should 
overcome the tangential stresses due to the body movements 
ensuring a strong and total adhesion to the skin for the entire 
time of application, as in the case of patches [47]. The 
substantivity is also one of the main attributes enabling the 
film to resist to removal, for example by clothing, or 
following cleansing of the skin surface [38].  
To assure the drying of the film forming formulation in a 
rather short time, the volatility of solvent(s) has to be 
evaluated. Organic solvents, e.g. short-chain alcohols, are 
generally preferable also because they guarantee the 
complete solubilization of the most used film-forming 
polymers. Among them, ethanol is the solvent of choice as 
the main regulatory agencies allow its use for topical 
application in concentrations higher than 95% [48, 49] and it 
can also act as a permeation enhancer [50]. In literature there 
are numerous examples of formulations containing different 
organic solvents (e.g. ethanol, isopropanol, ethyl acetate, 
acetone) alone or in mixture. However, the choice does not 
significantly influence the release profile from the FFS [43], 
even if they rapidly distribute in the stratum corneum [51]. 
Nevertheless, in some cases, a non-volatile component is 
also added to avoid drug precipitation during the formation 
of the film [51].  
The mechanical properties of the formed film are deeply 
influenced by the type and amount of polymer. An 
excessively low concentration can lead to the formation of 
discontinuous films or with poor mechanical resistance, 
while a high concentration solution produces thick and rigid 
films on the skin, which are uncomfortable and could delay 
the drug release [38]. A plasticizer is often added to increase 
the free volume between the polymer chains and, thus, 
increasing their mobility. These small molecules play a dual 
role not only assuring that the formed film completely adapts 
to the skin movements, but also decreasing the film forming 
temperature below the skin surface temperature.  
The creep compliance should be directly or indirectly 
measured to assure that the film overcomes the tangential 
stress due to the body movements. Gennari et al. proposed 
the evaluation of the tensile properties of the formed film to 
verify that its elastic modulus did not exceed that of the 
stratum corneum, in order to assure its intimate and 
prolonged contact [32]. Garvie-Cook et al. determined the 
elastic moduli of films based on Eudragit® RS by 
nanoindentation [52]. Despite the elastic moduli determined 
by AFM (Y=0.3 GPa) [53] were different an order of 
magnitude to those determined by texture analysis (Y=55 
MPa) [32Errore. Il segnalibro non è definito.], the 
minimum plasticizer concentration needed to obtain a 
flexible formulation was comparable, independently of the 
technique used to evaluate the film mechanical properties. 
Generally speaking, very few methods exist to probe the 
substantivity of dermal formulations and none of them is set-
up for FFS. Clinical studies evidenced that films constituted 
of hydrophilic polymers hardly guarantee the necessary 
substantivity to act as external drug reservoir [39] because 
they are easily removed by washing or sweating. Some 
Authors proposed an in vitro method to simulate the skin-to-
skin or clothing-to-skin contact and to determine the amount 
of formulation removed from the skin [53]. According to 
these preliminary data, FFS presented the highest 
substantivity with respect to the semi-solid preparations, 
such as creams and ointments [53]. 
The ability of a film to remain attached to the skin also 
depends on the interactions it establishes with proteins and 
lipids present on the skin surface. Since, at physiological pH, 
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the skin has a net negative charge, the films formed by 
cationic polymers show a greater substantivity than those 
formed by neutral or anionic polymers. Furthermore, also the 
possibility of forming hydrophobic interactions (such as 
hydrogen bonds or Van der Waals bonds) must be 
considered to evaluate the adhesive capacities of the film 
[38]. 
To avoid the adhesion to clothes, the film stickiness can be 
qualitatively tested by pressing cotton wool on the dried film 
under low pressure. Depending on the quantity of cotton 
fibers retained by the film, the stickiness can be rated as high 
(dense accumulation of fibers on the film), medium (thin 
fiber layer on the film) or low (occasional or no adherence of 
fibers). Similarly, adhesive properties can also be evaluated 
by a thumbtack test on the dried film [47]. On the other 
hand, a probe-tack test allows obtaining a quantitative and 
controlled measurement of the stickiness: a flat, solid punch, 
called probe, is brought into contact with the film deposited 
on a rigid substrate. The detachment force is then recorded 
while the probe is being pulled away [32]. 
 
 
Table 2 – Dosage forms and main components of film forming systems. 
Dosage form Active ingredient Polymer Solvent Ref 
 Betamethasone valerate Klucel™ LF; Kollidon® 12 PF/17 
PF/25/30; EC; CH; PAMA+; PME; 
PAOC 
Ethanol 54 
Betamethasone valerate HPC, PAMA+, PAOC  Ethanol 52 
Betamethasone valerate HPC, PAMA+, PAOC Ethanol 53 
Ethinylestradiol PAMA+, HPC, PU  Ethanol or ethanol/water 56 
Flurbiprofen 
Ketoprofen 
Ibuprofen 
PAMA+ Isopropyl alcohol/acetone 32 
Ketorolac PAMA+, Eudragit E, PVP K30 Ethanol 57 
Mupirocin PAMA Ethanol/acetone  58 
Oxybutynine Carbopol 940, Lutrol F127 Ethanol/acetone/methylal 59 
Metered dose spray Methylphenidate PAMA, PAMA+ Ethanol; isopropyl 
alcohol 
60 
Ropivacaine PAMA+, PAMA, PAA, HPC,  
polaxamer, PVA, PVP 
Ethanol; isopropyl 
alcohol 
61 
Betamethasone valerate PVP K90 Ethanol 62 
Testosterono PAMA+, Eudragit E, PVPS630, PVP 
K30 
Ethanol 41 
Dexketoprofen PAMA+, PVP K12, PVPS630, PVP 
K30 
Ethanol 63 
Fluconazole EC, PAMA+ Alcohol-acetone 64 
Lotion Testosterone PVP Isopropyl alcohol 65 
Emulsion Nonivamide  Water 66 
Nonivamide PAMA+ Water 67 
Nonivamide PME, PAMA+ Water 68 
Gel -- PVA Water 69 
Caffeine Fibroin Water/ethanol 44 
Ketoprofen CH Water/ethyl alcohol 70 
Rotigotine HPC and Carbomer 934 Water/ethanol 71 
Tolterodine Carbopol 980 (neutralized by 
triethanolamine), HPC, HPMC 
Water/ethyl alcohol 72 
PAMA+ poly(ammoniummethyl methacrylate) (Eudragit®RL or Eudragit®RS); PAMA poly(aminomethyl methacrylate) (Eudragit®E); PAA 
poly(methylmethacrylic acid) (Eudragit®L); HPC hydroxypropyl cellulose; polaxamer; PVA poly vinyl alcohol; PME polymethylethylacrylate (Eudragit NE); 
PVP polyvinyl pyrrolidone; EC ethyl cellulose; CH chitosan; HPCH hydroxypropyl chitosan; PAOC Acrylates/Octylacrylamide Copolymer (Dermacryl 79); 
PU polyurethane; HPMC hydroxypropyl methyl cellulose.  
 
The ability of the formulation to guarantee or enhance the 
skin penetration of drugs depends on the solvent(s), polymer 
and eventually plasticizer used to tune the mechanical 
properties. Not only the drug thermodynamic activity, but 
also the solvent evaporation rate can significantly influence 
the skin permeation from FFS. The relevance of both 
parameters is strictly related to the loaded drug, even within 
the same class of compounds [32Errore. Il segnalibro non 
è definito.]. In particular, the vehicle composition, apart 
from its function to solubilize both excipients and drugs, can 
influence the initial delivery of the latter into the skin, 
according to the solvent evaporation rate: the lower the 
evaporation rate, the higher the “burst” effect and the flux in 
the initial hours following drug application. The type and 
amount of polymer used can affect the ability of the formed 
film to control the drug release. For example, films made of 
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hydroxypropyl cellulose assure a zero-order kinetic for a 
prolonged period; while those obtained from acrylic and 
methacrylic polymers, more hydrophobic, can produce a 
more rapid burst effect, with the possibility of forming a 
drug reservoir in the stratum corneum [54]. The use of 
methyl methacrylate copolymers appears of interest [42, 52, 
54, 57, 68], even if the literature reports contrasting results 
on Eudragit® RL (EuRL) when it was compared to 
hydroxyethyl cellulose. As an example, the skin permeability 
of estradiol from EuRL based films resulted significantly 
lower than that obtained with the cellulose ether [39]. 
A second aspect influencing the skin permeation is the drug 
concentration and the applied amount of dosage form. In this 
case, the main criticism is related to drug crystallization that 
can occur also in relatively short period of time, affecting the 
whole permeation process through the skin. However, some 
polymers can act as anti-nucleating agents, inhibiting the 
drug crystallization over time [2, 52]. 
A plasticizer can influence the drug release whether the film-
forming formulation is a dispersion or a solution. In the first 
case, the plasticizer facilitates the coalescence of the polymer 
particles leading to the formation of a continuous and thick 
film, with a typically prolonged release profile. In the case of 
solutions, the presence of a plasticizer increases the mobility 
of the polymer chains, the diffusion capacity of the drug and 
its release profile [54, 73]. 
The drug diffusion and release can be also influenced by the 
environmental moisture, which can act as plasticizer of 
hydrophilic polymers.  
FFS, in whatever form (spray/solutions, gels or emulsions),  
can eventually include various other excipients, such as 
permeation enhancers and lipid excipients (medium-chain 
triglycerides), which can contribute to increase and prolong 
the drug release [54, 55].  
FFS can be formulated as solutions, sprays, gels and 
emulsions, the choice depending on the nature of the drug 
itself and the biopharmaceutical performance required. Gels 
generally facilitate and assist skin wound healing, since the 
formed film is more resistant to insults due to the movements 
of the skin. Interestingly, different topical gels present on the 
market can be considered as FFS, since polymers contained 
in these formulations show film-forming properties, even if 
the drying is slower than that of solutions. Some of these 
gelling agents are, for example, gellan gum (an anionic 
polysaccharide with high biocompatibility and reduced 
toxicity), carboxymethyl cellulose (in concentrations 
between 4 and 6%), carbomer, hydroxyethyl cellulose and 
hydroxypropyl methylcellulose. In case of emulsions, the 
W/O emulsion based FFS promoted the absorption of 
ethylhexyl methoxycinnamate, a lipophilic solar screen, as 
the oily component seems to have an occlusive effect on the 
skin. However, further studies showed that other lipophilic 
compounds, such as parabens, appear to cross the cutaneous 
layers better when administered in O/W emulsions probably 
because of their greater affinity for the skin surface with 
respect to formulation [74]. The selection of the dosage form 
influence also the application device to be selected. For 
instance, solutions are delivered to the skin through 
appropriate applicators or pre-dosed pump dispensers thus 
allowing the control of the administered dose. Gels are 
applied directly to the skin, especially in body regions such 
as arms, shoulders, abdomen and inner thigh.  
4. BIOPHARMACEUTICAL ASPECTS 
 The advantages of the MF and FFS compared to 
conventional formulations concern also biopharmaceutical 
aspects, since both have certainly demonstrated an 
improvement of bioavailability. Indeed, the metamorphosis 
to whom they undergo allows to generate a metastable 
supersaturated system. The consequent increase of drug 
thermodynamic activity appears a safer strategy with respect 
to chemical skin penetration enhancers usually used in the 
formulations of ointments, creams or gels. The literature data 
reports several in vitro studies aimed to compare the impact 
of these dosage forms on drug delivery, penetration and 
permeation through the stratum corneum.  
When thiocolchicoside was formulated as a foam, to avoid 
contact with the afflicted areas during the spreading phase, 
the drug accumulation into full human skin thickness was 
promoted in comparison with the simple drug solution [13]. 
Furthermore, the comparison among the in vitro permeation 
behavior of the foam, the commercial ointment and a control 
gel evidenced that the best permeation profile was obtained 
from the foam which allowed to increase the 
thiocolchicoside flux about 2- and 3-fold compared to 
ointment and gel, respectively [75]. 
The in vitro application onto the skin of clobetasol 
propionate (0.05%) formulated as a low-residue foam [76] 
improved the permeation rate with respect to other 
conventional semi-solid formulations [7]. Moreover, the in 
vitro application of clobetasol propionate foam to donor skin 
resulted in 5.9±1.1% drug accumulation after 12 h, compared 
with 2.8±0.3% with a solution, 2.7±0.3% with emollient 
cream, 2.1±0.2% with cream and 1.3±0.1% with lotion [77]. 
The same technology was also exploited to formulate a foam 
containing 2% ketoconazole for the treatment of mycoses 
and dermatological diseases, particularly seborrheic 
dermatitis. The foam allowed to accumulate in the epidermis 
a 2-fold higher amount of ketoconazole compared with a 
conventional cream [78]. Again, the use of a 0.12% 
betamethasone valerate foam for the treatment of psoriasis 
affecting the scalp and non-scalp regions of the body [70] 
improved the drug skin penetration both in terms of time and 
amount with respect to a lotion [79].  
FFS can be used to obtain both local and systemic effect. A 
very important application is the treatment of chronic 
dermatological diseases, such as atopic dermatitis and 
psoriasis, which require daily treatments preferably with 
topical action. This type of therapy, however, provides a 
large number of related adverse effects, such as toxicity 
caused by the application of corticosteroids, which, failing to 
permeate the skin layer, form depots on the surface of the 
skin. With the use of polymeric FFS, the permeation of these 
molecules through the stratum corneum was greatly 
increased: in a study carried out with a FFS based on 
betamethasone valerate, a drug depot in the skin was 
detected, about six times greater than that obtained with 
traditional topical dosage forms. It follows that, increasing 
the depot of the drug in the skin, the permeation is increased 
through the upper layers of the epidermis [62]. 
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Regarding FFS, estradiol was one of the first molecules to be 
loaded in the attempt to reach the systemic circulation after 
application of a spray on the skin [39]. As the results were 
immediately satisfactory, in the last years several FFS have 
been placed on the market for the administration of estradiol, 
terbinafine (human) and fentanyl (veterinary) and many 
others are in planning or in experimental phases. 
FFS are able to enhance the skin penetration also in 
comparison with transdermal patches as demonstrated in the 
case of ethinyl estradiol [56].  
Several studies were carried out with the intent of evaluating 
the function of the drug "reservoir" on the skin surface. For 
example, when a formulation based on fentanyl in a volatile 
solvent was applied topically, more than 50% of the initial 
dose remained on the skin surface as a residue, while only 
20% permeated through the stratum corneum, in a 24-hour 
period [80]. Hence, despite the large amount, the drug on the 
skin surface has only a minor importance in the maintenance 
of therapeutic effects. As an example, Evamist®, a film-
forming formulation currently on the market for the delivery 
of estradiol, delivers 21 μg of estradiol, while the applied 
dose is 1.53 mg. The washing, performed after 30 min from 
the application to remove the excess of drug deposited on the 
skin surface, does not drop down the estradiol bioavailability 
[81]. However, the poor efficiency, intended as the dose 
absorbed by the skin with respect to the applied dose [82], is 
typical of all topical dosage forms including patches, since 
the absorption is governed by the chemical potential.  
In addition to estradiol, testosterone and some progestins 
were also included in FFS for the treatment of androgen 
deficit in men [65] and contraception [83]. In particular, 
nestorone (a 19-norprogesterone derivative) was formulated 
in a pre-dosed polymeric FFS and applied three times a day 
to the forearm of six postmenopausal women. Clinical data 
evidenced that the concentrations reached through this route 
of administration and the obtained pharmacokinetics have 
effectively led to a blockage of ovulation and, therefore, to 
the desired contraceptive effect. 
5. ADHERENCE TO TOPICAL TREATMENTS 
 “Adherence to medications” is defined as “the 
process by which patients take their medications as 
prescribed” [84] and “non-adherence to medications” is thus 
defined as “late or non-initiation of the prescribed treatment, 
sub-optimal implementation of the dosing regimen or early 
discontinuation of the treatment” [61, 84]. Poor medication 
adherence is a worldwide problem associated to negative 
health outcomes and increased health care costs. 
The issue of patient adherence to topical drugs is particularly 
significant in relation to chronic skin diseases, including 
psoriasis, atopic dermatitis, and acne, which require long-
term use of topical medications. Several factors make 
adherence to topical treatment of skin disease different from 
other medication adherence issues. Patients with skin disease 
may be more likely to adhere to their treatment regimens 
because dermatological diseases are more visible and highly 
symptomatic, and because topical treatments have few 
systemic side effects. On the other hand, patient adherence 
may suffer as topical treatments are more time-consuming 
and complicated to use than oral treatments. Indeed, 
ambiguous and subjective usage and dosing instructions (e.g. 
“apply sparingly”) may lead to incorrect use of topical drugs. 
Complicated application instructions may be more difficult 
to understand or remember, and result in more frequent 
misuses compared to oral therapy (e.g. ‘take one tablet 
daily'); patients may be put off by topical treatments' non-
aesthetic and galenic nature (e.g. messiness, smell, 
spreadability, and discoloration), or side effects such as 
irritation, burning, and dryness [85].  
Formulations or dosage forms to be applied onto the skin 
could contribute to greater medication adherence and better 
treatment outcomes. As an example, patches do not always 
have excellent esthetic properties, since, under certain 
conditions, they can be clearly visible, thus reducing patient 
compliance. Semi-solid formulations (gels and ointments) 
may result, in some forms, more discreet than patches, but 
they cannot always guarantee a prolonged adhesion to skin 
surface, also because they are easily removable in contact 
with clothing. Moreover, ointments leave sticky and oily 
skin surface after application, further decreasing patient 
compliance [62, 86]. Another problem related to wear and 
tear is the time needed to dry these formulations, which can 
be quite long, and often they require rather large areas of 
application, making the administration even more 
uncomfortable.  
Despite many reports underline that patient’s preferences for 
the various topical formulations are highly variable [87], 
both medicated foams and FFS could solve, or at least 
reduce, some of these problems and, therefore, improve the 
adherence. Indeed, these dosage forms can reduce the 
frequency of administration and the duration of the treatment 
period. As an example, FFS containing the antifungal 
terbinafine allows a once-a-day administration to overcome 
the issues related to multiple administrations required by 
traditional formulations (gels or ointments) [88, 89]. For 
patients who prefer a less messy vehicle, adherence and 
outcomes are likely to be better with these formulations 
compared with the traditionally recommended ointment. 
Moreover, due to evaporation of the propellant or volatile 
solvent(s), both formulations can leave a fresh sensation on 
the inflamed skin [90]. Furthermore, the design of low 
viscosity formulations can facilitate their application on the 
skin. Recently, a fixed-combination calcipotriene 0.005% 
and betamethasone dipropionate 0.064% formulated as a 
foam was proposed as an alternative to the corresponding 
ointment and gel in the treatment of psoriasis vulgaris. In 
such formulation the use of dimethyl ether and butane 
mixture used as propellant allows formation of a stable 
supersaturated system which enhances skin penetration of 
both loaded active substances compared to an ointment. 
Following once-daily topical application, preference data 
indicated that younger patients (aged 18-39 years) receiving 
the foam thought it was more effective and easier to apply 
than the gel [91]. After 15 days of use, 94% patients with 
mild to severe psoriasis would recommend foam to other 
patients with psoriasis, with 73% being very likely to do so 
[92]. 
In case of FFS, the appreciation of patients is related to the 
discretion of the film applied on the skin so that, thanks to 
their transparency, FFS are often referred as “transparent 
patches”. This feature was demonstrated to improve the 
patient compliance, above in case of some treatments, such 
as hormone replacement therapy and smoking cessation, for 
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which privacy is one the main concerns of the patients. 
Therefore, dosage forms simple to hide and almost invisible 
after application, such as FFS, are very attractive.  
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